Opexa Therapeutics held a conference call Conference call to discuss the option and license agreement with Merck Serono for development of Tcelna for treatment of Multiple Sclerosis was held on February 5 at 8:30 am and has a webcasted replay available. Webcast Link
News For OPXA From The Last 14 Days
Check below for free stories on OPXA the last two weeks.
Opexa Therapeutics terminates public offering of common stock Opexa Therapeutics announced that it has terminated the public offering of shares of its common stock previously announced on Monday, September 15. The termination results from an assessment by Opexa’s management that current market conditions are not conducive for an offering on terms that would be in the best interests of Opexa’s stockholders. As a result of such termination, no shares will be sold pursuant to the offering.